Market Cap 3,000.00
Revenue (ttm) 540,000.00
Net Income (ttm) -5.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -937.04%
Debt to Equity Ratio 0.00
Volume 200
Avg Vol N/A
Day's Range N/A - N/A
Shares Out 803,000.00
Stochastic %K N/A
Beta -2.03
Analysts Strong Buy
Price Target $1.00

Company Profile

Cardax, Inc., a biopharmaceutical company, develops and commercializes dietary supplements for inflammatory health and pharmaceuticals for chronic diseases driven by inflammation and oxidative stress. It offers ZanthoSyn, an inflammatory supplement for health and longevity that provides astaxanthin with enhanced absorption and purity. The company sells ZanthoSyn primarily through e-commerce and wholesale channels. It is also developing CDX-101, an astaxanthin pharmaceutical candidate for cardiov...

Industry: Biotechnology
Sector: Healthcare
Phone: 808 457 1400
Fax: 808 237 5901
Address:
2800 Woodlawn Drive, Suite 129, Honolulu, United States
Latest News on CDXI
No data available.